Newt & Nanjing Hanxin
Newt's legal entity in China is Nanjing Hanxin Pharmaceutical Technology Co., Ltd., a member company of the U.S. AMPHASTAR Pharmaceutical Group. The company is dedicated to the research, development, manufacturing and sale of animal-derived materials, biologically fermented raw materials and finished pharmaceutical products. Its core technical team brings extensive industry experience and a strong understanding of Chinese and international new-drug regulations, providing innovative drug developers with end-to-end solutions spanning product development, laboratory-scale studies, pilot-scale production and commercial manufacturing.
Purpose-built production areas and automated equipment support GMP-aligned procedures, standardized handling, repeatable workflows and consistent quality control.
Dedicated analytical spaces bring instruments, sample preparation and documentation review into a controlled laboratory workflow.
Technical personnel coordinate laboratory work, analytical review and project information for clear communication across each stage.
Newt regularly participates in industry exhibitions in China and around the world, engaging directly with research buyers and industry partners.
Founded in 1996 and headquartered in California, Amphastar Pharmaceuticals develops, manufactures and markets more than 60 injectable and inhalation products under FDA cGMP requirements. The company has been listed on Nasdaq since 2014 (NASDAQ: AMPH), with subsidiaries in the United States, China and Europe, more than 200,000 m² of facilities and over 2,000 employees.
The original business license for Nanjing Hanxin Pharmaceutical Technology Co., Ltd. is available for direct review, together with an English translation for international buyers.
Original Chinese registration document Open PDF →
Our team supports qualified research buyers with product documentation, order coordination and responsive assistance throughout the procurement process.
